Exagen Inc. (NASDAQ: XGN) reported Q2 EPS of $0.16, $0.50 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $15.1 million versus the consensus estimate of $13.13 million.

GUIDANCE:

Exagen Inc. sees FY2024 revenue of $57 million, versus the consensus of $55.75 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.